DEC 03, 2021 1:00 PM PST

FDA approves new imaging drug to make ovarian cancer tumors glow.

WRITTEN BY: J. Bryce Ortiz

Earlier this week, the United States Food and Drug Administration (FDA) announced its approval for a novel drug that can be used to make ovarian tumors glow. The drug was developed in order to assist surgeons in identifying and removing tumors and cancerous cells during surgical cancer removal. The drug was designed and developed at Purdue University and is being released for market by the biotech company On Target Labs

According to the Centers for Disease Control, ovarian cancer is the second most common gynecological cancer in the United States. Ovarian cancer occurs when cancerous cells invade the ovaries, multiply quickly, and destroy healthy tissue. Ovarian cancer is survivable if treated correctly. Treatment usually involves chemotherapy and surgery to remove the tumor and cancerous cells. However, cancer surgery can be complicated by multiple challenges that include localizing and identifying tumors and ensuring all cancerous cells have been removed. Because of these challenges, the novel drug called Cytalux was developed to mark cancer cells with a fluorescent tag that allows the cells to glow during surgery. 

The drug is delivered via an intravenous injection 1 to 9 hours prior to surgery. The drug attaches to the cancer cells which allows surgeons to easily visualize the cancer. Dr. Philip Low, a professor of chemistry at Purdue University who helped develop the drug, said that when the drug is administered and the surgeon turns on the near-infrared light, the cancer cells, “light up like stars against a night sky.” He also added, “It seems to me that future [cancer removal] surgeries are going to very heavily rely on this technology.”

The FDA-approval of the drug is based on a successful Phase 3 clinical trial that tested the drug. In the study, patients with ovarian cancer underwent surgery to remove the cancer. It was found that in 109 patients with ovarian cancer, surgeons were able to easily and accurately identify and remove the primary tumor. Importantly, the surgeons intraoperatively identified additional cancer not originally planned for resection in a statistically significant number of patients. Lastly, there were no serious drug-related adverse events. The FDA-approval of the drug is a significant milestone in cancer treatment and will help to significantly prevent ovarian cancer related deaths. 

 

Sources: FDAClinical Cancer ResearchOn Target LabsCDCJournal of Clinical Oncology

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
NOV 19, 2021
Health & Medicine
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
NOV 19, 2021
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
A recent study by Columbia University and Weill Cornell Medicine researchers found that cannabis use disorder (CUD) in p ...
DEC 11, 2021
Health & Medicine
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
DEC 11, 2021
Third Dose of Pfizer-BioNTech Vaccine Could Reduce Effects of Omicron
Many mainstream media sources are reporting on a new press release from Pfizer that suggests that a third dose of the Pf ...
DEC 23, 2021
Cancer
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
DEC 23, 2021
Optimizing the Recovery Room Could Help Reduce the Recurrence of Bladder Cancer
It is estimated that nearly 84,000 people will be diagnosed with bladder cancer in the United States this year ...
JAN 01, 2022
Health & Medicine
Novavax's More Traditional COVID-19 Vaccine Gets Approval From European Commission and World Health Organization
JAN 01, 2022
Novavax's More Traditional COVID-19 Vaccine Gets Approval From European Commission and World Health Organization
Novavax, a Maryland-based biotechnology company, gets approval for its more traditional protein-subunit COVID-19 vaccine ...
JAN 27, 2022
Clinical & Molecular DX
Eye Opening: Some Patients Can Safely Wean off Vision Loss Treatment
JAN 27, 2022
Eye Opening: Some Patients Can Safely Wean off Vision Loss Treatment
Age-related macular degeneration (AMD) is a progressive vision impairment resulting from the deterioration of the retina ...
JAN 24, 2022
Microbiology
Potential Anti-Cancer Bacterium Found in Antarctic Sea Squirt
JAN 24, 2022
Potential Anti-Cancer Bacterium Found in Antarctic Sea Squirt
Some of our best medicine has come from nature, and scientists are always on the lookout for natural products that can b ...
Loading Comments...